2013 American Transplant Congress
Liver Preservation with Machine Perfusion under Full Oxygenation Using a New Cell-Free Oxygen-Carrier Solution
Background: Machine perfusion (MP) has been implemented either under hypothermic and anoxic conditions or under normothermia with full oxygenation using blood as perfusate. This is…2013 American Transplant Congress
Long Term Clinical Outcome of Liver Transplant Recipients Who Successfully Withdrawn Immunosuppression, The
UOC Chirurgia dei Trapianti, Tor Vergata University, Rome, Italy
Background. Clinical operational tolerance was defined as stable normal graft function in the total absence immunosuppression (IS). It may be achieved in up to 20%…2013 American Transplant Congress
Short-Term Outcomes of the Calcineurin Inhibitor Avoidance Maintenance Regimen with Everolimus in Kidney Transplant Recipients
Department of Surgery, Kidney Center, Tokyo Women's Medical University, Tokyo, Japan
Background: Everolimus (EVR)-based calcineurin inhibitor (CNI)–free regimen has been used to avoid CNI toxicity, although it was not concluded for conversion in kidney transplant recipients…2013 American Transplant Congress
C1q-Fixing Human Leukocyte Antigen Assay for Chronic Antibody-Mediated Rejection in Renal Transplant Recipients
(Background)Antibodies against human leukocyte antigens (HLAs) are associated with the antibody-mediated rejection and ultimately graft loss. The standard assays used to detect antibodies against HLAs…2013 American Transplant Congress
Leflunomide Confers Protection to the Post-Ischemic Kidney Via Inhibition of GADD153 Expression and Inflammation
Background: Ischemia reperfusion injury is associated with a number of clinical conditions including renal transplantation. We recently showed that pretreatment of mice with leflunomide significantly…2013 American Transplant Congress
High MFI Preformed Class II HLA Donor Specific Alloantibodies Increase the Risk of Early Rejection and Death after Liver-Transplantation
Aim: To evaluate the impact of preformed donor specific alloantibodies (DSA) on the risk of rejection and patient survival after isolated liver transplantation (LT). Methods:…2013 American Transplant Congress
Early Elevated Everolimus Levels Are Associated with More Toxicities without Improved Efficacy
Transplant, MUSC, Charleston, SC
Background: Everolimus (ERL) is an mTOR generally utilized in CNI minimization or withdrawal regimens for kidney transplantation (KTX). The aim of this study was to…2013 American Transplant Congress
Comparison of Everolimus Pharmacokinetics and Pharmacodynamics between Ethnicities
Transplant, MUSC, Charleston, SC
Background: Everolimus is an mTOR generally utilized in CNI minimization or withdrawal regimens for kidney transplantation. The aim of this study was to compare pharmacokinetic…2013 American Transplant Congress
Actuarial Perspective on the Annual Per Patient Maintenance Immunosuppressive Medication Costs for Transplant Recipients: 1993-2011, An
United Network for the Recruitment of Transplantation Professionals, Rochester, MN
The annual per patient cost of immunosuppressive medications for transplant recipients is highly variable, and poorly understood.Since 1993, insurance actuaries have periodically published estimates of…2013 American Transplant Congress
Long-Term Assessment of Function in Patients Completing the Spare-the-Nephron Study with a Functioning Graft
Div of Nephrology, Dept of Medicine, Univ of Maryland School of Medicine, Baltimore, MD
In the Spare-the-Nephron (STN) study (Weir MR et al. Kidney Int 2011;79:897-907) kidney transplant recipients randomized about 115 days post-transplant to convert from CNI (calcineurin…
- « Previous Page
- 1
- …
- 158
- 159
- 160
- 161
- 162
- …
- 178
- Next Page »